Scarica l'app Stockscreener
9.265
4.69%
0.415
Sensei Biotherapeutics Inc Borsa (SNSE) Ultime notizie
Sensei Biotherapeutics (SNSE) Trading Halted Amid Pending News | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split | - GuruFocus
Sensei Biotherapeutics to implement 1-for-20 reverse stock split - Investing.com Australia
Sensei Biotherapeutics to implement 1-for-20 reverse stock split By Investing.com - Investing.com Canada
Sensei Biotherapeutics announces reverse stock split By Investing.com - Investing.com Canada
Sensei Biotherapeutics to Implement 1-for-20 Reverse Stock Split - MarketScreener
Sensei Biotherapeutics Announces Reverse Stock Split - TipRanks
Sensei Biotherapeutics Sets 1-for-20 Reverse Stock Split - Nasdaq
Sensei Biotherapeutics announces reverse stock split - Investing.com
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split | SNSE Stock News - GuruFocus
Sensei Biotherapeutics (SNSE) Announces 1-for-20 Reverse Stock Split | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Announces 1-For-20 Reverse Stock Split - marketscreener.com
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split - GlobeNewswire
Sensei Bio's 1:20 Reverse Split Slashes Outstanding Shares from 25M to 1.3MWhat Investors Must Know - Stock Titan
What is HC Wainwright’s Forecast for SNSE Q2 Earnings? - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Upgraded at HC Wainwright - Defense World
Sensei Biotherapeutics (SNSE) Receives a 'Buy' Rating from HC Wainwright | SNSE Stock News - GuruFocus
Sensei Biotherapeutics (SNSE) Receives Buy Rating from H.C. Wain - GuruFocus
Sensei Biotherapeutics (SNSE) Receives Buy Rating from H.C. Wainwright | SNSE Stock News - GuruFocus
H.C. Wainwright assumes Buy rating on Sensei Biotherapeutics stock By Investing.com - Investing.com Canada
VISTA Inhibitor Clinical Trials Market Insights and Drug Development Opportunities Report 2025-2028 Featuring Aurigene, Curis, Hummingbird Bioscience, Kineta, PharmAbcine, Sensei BiotherapeuticsResearchAndMarkets.com - FinancialContent
Sensei Biotherapeutics stockholders approve key proposals By Investing.com - Investing.com Nigeria
Sensei Biotherapeutics stockholders approve key proposals - Investing.com
Sensei Biotherapeutics Approves Reverse Stock Split - TipRanks
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Sold by Renaissance Technologies LLC - Defense World
Sensei Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Qua - GuruFocus
Sensei Biotherapeutics Reports Promising Q1 2025 Results - TipRanks
Sensei Biotherapeutics Reports First Quarter 2025 Financial Resu - GuruFocus
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Quarter | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress - The Manila Times
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress | SNSE Stock News - GuruFocus
Sensei Bio's Cancer Drug Achieves Breakthrough: 3X Better Response in PD-L1 Resistant Patients - Stock Titan
Sensei Biotherapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
SEC Form DEF 14A filed by Sensei Biotherapeutics Inc. - Quantisnow
Penny Stocks To Add to Your WatchlistMarch 30th - MarketBeat
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - The Manila Times
Promising Penny Stocks To ResearchMarch 29th - MarketBeat
Best Penny Stocks To Follow NowMarch 28th - MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sensei Biotherapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Sensei Biotherapeutics stock hits 52-week low at $0.34 - Investing.com
HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE) - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer - Armenian Reporter
Sensei Biotherapeutics Reports Promising 2024 Results - TipRanks
Sensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves - GuruFocus
Sensei stock holds Buy rating, $4 target from H.C. Wainwright By Investing.com - Investing.com Australia
Sensei Rockets on FY ’24 Results - Baystreet.ca
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):